Navigation Links
Synexus Celebrates 21st Birthday With a Forward Order Book of Over $100 Million
Date:4/9/2013

MANCHESTER, England, April 9, 2013 /PRNewswire/ --

Since its launch 21 years ago Synexus has grown from a small clinic adjoining founder Dr Smith's surgery to the largest multinational organisation dedicated to the recruitment of patients and running of clinical trials at its 25 clinics across Europe and Africa.

Dr Christophe Berthoux , CEO of Synexus said: "We had an excellent 2012 and expect 2013 to be better. Our forward order book, which at this time exceeds $100 million, continues to grow. In the last two years we have undergone dramatic and positive change. To meet the growth in demand we have strengthened our management team and focussed on the therapy areas where we can add most value - cardiovascular, metabolic (diabetes and obesity), bone, respiratory and CNS (dementia and pain)."

The reorganisation includes a new global management team, reporting to the executive management board, which is responsible for HR, IT and patient recruitment. This has resulted in great improvement in patient recruitment with over 95% of trials achieving or exceeding their targets.

Synexus has also put in place a regional structure with managing directors being responsible for their regions including the day-to-day running of their sites, performance and profitability.

All regions report to COO Jane Restorick who has an overriding responsibility for data quality, patient care and the adherence of best clinical practice in every Synexus clinic.

Christophe explains the success of the Synexus model "We've seen our model being adopted far more widely as our clients in pharma and CROs get to grips with the urgent need to bring drugs to market more quickly and less expensively."

Synexus has shown that using its own Centres speeds up clinical trials, makes them more cost-effective and delivers thousands of patients. It has revolutionized the way late-stage clinical trials are carried out.  Traditionally, individual doctors recruited four patients or less on an opportunistic basis which, with studies involving thousands of patients, is enormously expensive and wholly impractical.

Christophe sums up "Our excellent progress is directly related to putting in place a professional structure which delivers quality data and patients. It has been a team effort which has been actively supported by our major shareholder Lyceum Capital. We are looking forward to a sustained period of growth."

INFORMATION:  
Simon Vane Percy
+44-(0)1737-821-890 / +44(0)7710-005910
simon@vanepercy.com



'/>"/>
SOURCE Synexus
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Chicago Celebrates First Informatics Week, Co-Chaired by Intelligent Medical Objects and Northwestern University
2. OBNs 2012 Annual Awards Dinner Celebrates UK Bioscience Success Stories
3. Christmas Special: My Cleaning Products Celebrates Holiday With a Molderizer and Safe Shield Markdown for its Clients
4. Dallas-Fort Worth Fertility Associates Celebrates First Birth in North Texas from Advanced Trophectoderm Biopsy Screening Technology
5. Identigene Turns 20! Identigene DNA Laboratory Celebrates 20 Year Anniversary
6. How Hot or Cold is it? H-B Instrument Puts Celebrates 110 Years of Manufacturing High-Quality Thermometers and More
7. Amphora Research Systems Celebrates its Tenth Birthday
8. Stoneville Cotton Seed from Bayer CropScience Celebrates 90 Years of Performance
9. Graphite Metallizing Celebrates 100th Anniversary
10. Pi Day is coming March 14! National Pi Day Celebrates Education and its Importance in All Our Lives
11. American Farmer Recognizes and Celebrates National Agriculture Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance ... consulting, provides a free webinar on Performing Quality Investigations: Getting to ... 12pm CT at no charge. , Incomplete investigations are still a major concern ...
Breaking Biology Technology:
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
Breaking Biology News(10 mins):